Drugs / Olvimulogene nanivacirepvec
Olvimulogene nanivacirepvec
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02714374 | Mar 2016 → Aug 2019 | cancer | Andrew Lowy | Terminated | No outcome recorded |
| Phase 1 | NCT01766739 | Jan 2013 → Oct 2024 | lung cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01584284 | Apr 2012 → Jun 2015 | head and neck cancer | Genelux GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00794131 | Nov 2008 → Nov 2015 | cancer of unknown primary site | Genelux GmbH | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07136285 | Jul 2023 → Dec 2026 expected | small cell lung carcinoma | Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02759588 | May 2016 → Dec 2021 | fallopian tube cancer, ovarian cancer, peritoneal carcinomatosis | Genelux GmbH | Completed | No outcome recorded |
| Phase 1/2 | NCT01443260 | Feb 2012 → Sep 2014 | peritoneal carcinomatosis | Genelux GmbH | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06463665 | Sep 2024 → Feb 2027 expected | non-small cell squamous lung carcinoma | Genelux GmbH | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05281471 | Aug 2022 → Dec 2026 expected | fallopian tube carcinoma, ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian serous adenocarcinoma +2 | Genelux GmbH | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03420430 Background | — | acute myeloid leukemia | Genelux GmbH | No longer available | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | olvimulogene nanivacirepvec | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05281471 ↗ |
| Known as | GL-ONC1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01584284 ↗ |
| Known as | Glv-1h68 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594308 ↗ |
| Known as | Olvi-vec | “Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma.” PMID 36875061 ↗ Feb 2023 |
| Known as | Olvimulogen nanivacirepvec | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594308 ↗ |
| Modality | Other / unclassified | “an oncolytic vaccinia virus” NCT01443260 ↗ |
| Route | Intravenous | “administered intravenously” NCT00794131 ↗ |